Your gym friend may mean well, but they should not be the person deciding what you inject into your body.

In this episode, Dr. Albert Takem explains why “microdosing Ozempic” is not a real medical strategy, why compounded GLP-1 products are not the same as FDA-approved medications, and what patients should ask their doctor before starting or continuing weight loss medication.

The episode follows the story of Kim, a 59-year-old active patient who was doing many things right but started using compounded semaglutide after hearing about it from friends at the gym. Dr. Takem breaks down the difference between social media trends, compounded products, and medically supervised maintenance dosing.

We discuss:

• Why “microdosing Ozempic” is a marketing term, not a medical term
• The difference between compounded GLP-1 products and FDA-approved medication
• Why dosing errors can happen with compounded semaglutide
• What medical organizations have said about compounded GLP-1 products
• Why stopping GLP-1 medication often leads to weight regain
• What maintenance dosing actually means
• Safer questions to ask your doctor before using compounded medication

Your body is not a science experiment. If you are using a compounded GLP-1 product or trying to adjust your dose on your own, talk to your doctor about safer, FDA-approved options.

Questions for Dr. Takem and the team

💡 Start your journey today with Maryland Primary Care & Wellness
Book your consultation: https://www.maryland-primarycare.com/